CIK 0001850119
- Emerging growth company
Century Therapeutics, Inc.
Sign in to watch- Ticker
- IPSC
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 842040295
- Phone
- +1 215-981-4000
- Business address
- 25 N 38TH STREET, 12TH FLOOR, PHILADELPHIA, PA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $10,212
- in 5 filings
Net −$10,212. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-02-02 | Russotti Gregory Chief Technology Officer | Grant or award · Stock Option (right to buy) | +175,000 | 175,000 | ||
| 2023-02-02 | Borges Luis Chief Scientific Officer | Grant or award | +21,875 | 21,875 | ||
| 2023-02-02 | Borges Luis Chief Scientific Officer | Grant or award | +21,875 | 43,750 | ||
| 2023-02-02 | Borges Luis Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +131,250 | 131,250 | ||
| 2023-02-02 | Borges Luis Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +131,250 | 131,250 | ||
| 2023-02-02 | Farid Adrienne Chief Operations Officer | Grant or award | +21,875 | 96,093 | ||
| 2023-02-02 | Farid Adrienne Chief Operations Officer | Grant or award | +21,875 | 117,968 | ||
| 2023-02-02 | Farid Adrienne Chief Operations Officer | Grant or award · Stock Option (right to buy) | +131,250 | 131,250 | ||
| 2023-02-02 | Farid Adrienne Chief Operations Officer | Grant or award · Stock Option (right to buy) | +131,250 | 131,250 | ||
| 2023-02-02 | Diem Michael Craig Chief Business Officer | Grant or award | +21,875 | 101,363 | ||
| 2023-02-02 | Diem Michael Craig Chief Business Officer | Grant or award | +21,875 | 123,238 | ||
| 2023-02-02 | Diem Michael Craig Chief Business Officer | Grant or award · Stock Option (right to buy) | +131,250 | 131,250 | ||
| 2023-02-02 | Diem Michael Craig Chief Business Officer | Grant or award · Stock Option (right to buy) | +131,250 | 131,250 | ||
| 2022-10-01 | Quimi Daphne Director | Grant or award · Stock Option (right to buy) | +39,744 | 39,744 | ||
| 2022-10-01 | Walbert Timothy P Director | Grant or award · Stock Option (right to buy) | +39,744 | 39,744 | ||
| 2022-08-09 | Versant Venture Capital VI, L.P. 10% owner | Sale | −550,000 | $13.03 | $7.2M | 11,816,814 |
| 2022-08-09 | Versant Venture Capital VI, L.P. 10% owner | Other disposition | −364,800 | 11,452,014 | ||
| 2022-06-09 | BUTITTA CYNTHIA M Director | Grant or award · Stock Option (right to buy) | +19,872 | 19,872 | ||
| 2022-06-09 | Riva Alessandro Director | Grant or award · Stock Option (right to buy) | +19,872 | 19,872 | ||
| 2022-06-09 | Blackwell Kimberly Director | Grant or award · Stock Option (right to buy) | +19,872 | 19,872 |
Page 10 of 12 · 233 trades